BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 2116226)

  • 1. Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect.
    Huang J; Wu R; Chen L; Yang Z; Yan D; Li M
    Front Pharmacol; 2022; 13():811406. PubMed ID: 35211017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers.
    Chen D; Kelly C; Haw TJ; Lombard JM; Nordman IIC; Croft AJ; Ngo DTM; Sverdlov AL
    Curr Heart Fail Rep; 2021 Dec; 18(6):362-377. PubMed ID: 34731413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
    Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
    Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
    Alderton PM; Gross J; Green MD
    Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
    Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
    Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
    Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).
    Herman EH; Ferrans VJ
    Cancer Res; 1981 Sep; 41(9 Pt 1):3436-40. PubMed ID: 6790165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotective agents for anthracyclines.
    Dorr RT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.
    Seifert CF; Nesser ME; Thompson DF
    Ann Pharmacother; 1994 Sep; 28(9):1063-72. PubMed ID: 7803884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
    Green MD; Alderton P; Sobol MM; Gross J; Muggia FM; Speyer JL
    Cancer Treat Res; 1991; 58():101-17. PubMed ID: 1683780
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.